Other Trials Clinical Trials

Showing 1-5 of 5 items
1.
  • Bortezomib Plus Rituximab for Initial Therapy of EBV+ PTLD
  • Post transplant lymphoproliferative disease (PTLD) is a type of B-cell non-Hodgkin lymphoma that occurs in patients with weakened immune systems due to immunosuppressive medications taken after organ or stem cell transplantation. This is usually related to a virus called Epstein-Barr (EPV). Rituximab is a type of drug called an "antibody" that specifically destroys both normal and cancerous B-cells, and is commonly used for PTLD. Bortezomib is a drug that has been approved by the Food and Drug Administration (FDA) to treat multiple myeloma and a B-cell non-Hodgkin lymphoma called Mantle Cell Lymphoma, and shows significant activity in lymphoma cells caused by EBV. In this research study, we hope to learn if the addition of bortezomib to rituximab treatment can increase the rate of complete remissions and cures of PTLD after organ or stem cell transplant.
  • Diagnoses: Other Trials
  • Status: Recruiting
2.
  • Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash
  • This is a clinical research study of an experimental new medication, Menadione Topical Lotion (MTL). The study lotion is experimental and has not been approved for public use. Hana Biosciences, Inc., the company that is developing MTL, is the sponsor of this study. EGFR inhibitors are used to treat non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer, breast cancer and head and neck cancer. One of the side effects of EFGR inhibitors is skin toxicites including an acneform skin rash. This study is a Phase 1 study. The main purposes of this study are: - Evaluate the safety and tolerability of Menadione Topical Lotion as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash - Evaluate the systemic absorption and bioavailability of Menadione Topical Lotion as an emergent and pre-emergent treatment for EGFR inhibitor-associated rash It is planned that up to 24 patients undergoing EGFR inhibitor therapy will take part in this study at multiple clinical centers.
  • Diagnoses: Other Trials
  • Status: Recruiting
3.
  • Fludarabine-based Conditioning for Severe Aplastic Anemia
  • The purpose of this study is to continue to optimize conditioning regimens in high-risk patients with severe aplastic anemia (SAA) transplanted with marrow from human leukocyte antigen (HLA)-compatible unrelated donors. Specifically, the study will address whether the addition of fludarabine to the conditioning regimen of Deeg et al. will permit reduction in the cyclophosphamide (CY) dose to a point where survival is maintained or improved and sustained hematopoietic engraftment is maintained or improved with reduced major regimen-related toxicity (RRT) and/or early death.
  • Diagnoses: Other Trials, Pediatric Hematology/Blood Related
  • Status: Recruiting
4.
5.
Showing 1-5 of 5 items
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms